Qube Research & Technologies (QRT)
REGN icon

Qube Research & Technologies (QRT)’s Regeneron Pharmaceuticals REGN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.4M Sell
83,358
-58,825
-41% -$45M 0.07% 337
2025
Q4 		$110M Sell
142,183
-406,551
-74% -$276M 0.11% 216
2025
Q3 		$309M Sell
548,734
-77,246
-12% -$43.7M 0.32% 51
2025
Q2 		$329M Sell
625,980
-76,912
-11% -$42.9M 0.33% 49
2025
Q1 		$446M Buy
702,892
+261,238
+59% +$180M 0.52% 24
2024
Q4 		$315M Buy
441,654
+289,685
+191% +$243M 0.41% 28
2024
Q3 		$160M Sell
151,969
-41,979
-22% -$46.7M 0.24% 82
2024
Q2 		$204M Buy
193,948
+38,100
+24% +$36.9M 0.32% 51
2024
Q1 		$150M Sell
155,848
-15,516
-9% -$14.8M 0.24% 96
2023
Q4 		$151M Buy
171,364
+165,621
+2,884% +$136M 0.29% 70
2023
Q3 		$4.73M Buy
+5,743
New +$4.51M 0.01% 958
2023
Q2 		– Sell
-4,519
Closed -$3.71M – 2899
2023
Q1 		$3.71M Sell
4,519
-102,160
-96% -$77.1M 0.02% 756
2022
Q4 		$77M Buy
106,679
+98,996
+1,289% +$73M 0.41% 33
2022
Q3 		$5.29M Sell
7,683
-75,067
-91% -$47.2M 0.03% 604
2022
Q2 		$48.9M Buy
82,750
+73,120
+759% +$47.5M 0.36% 50
2022
Q1 		$6.73M Sell
9,630
-11,030
-53% -$6.98M 0.06% 432
2021
Q4 		$13M Sell
20,660
-15,985
-44% -$9.83M 0.1% 244
2021
Q3 		$22.2M Buy
+36,645
New +$22.7M 0.28% 65
2021
Q1 		– Sell
-26,622
Closed -$12.9M – 2327
2020
Q4 		$12.9M Buy
26,622
+3,152
+13% +$1.7M 0.18% 105
2020
Q3 		$13.1M Buy
+23,470
New +$14.2M 0.19% 118
2019
Q3 		– Sell
-5,766
Closed -$1.8M – 418
2019
Q2 		$1.8M Buy
+5,766
New +$1.92M 0.43% 59
2018
Q4 		– Sell
-2,756
Closed -$1.11M – 761
2018
Q3 		$1.11M Buy
+2,756
New +$1.05M 0.15% 112

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Qube Research & Technologies (QRT)'s REGN Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Regeneron Pharmaceuticals (REGN) stake by 41% in Q1 2026, selling an estimated $45M and leaving 83,358 shares worth $64.4M. The position accounts for 0.07% of the portfolio, ranked #337.

Qube Research & Technologies (QRT) first reported a position in REGN in Q3 2018 and has held it in 22 quarters since. The position peaked at $446M in Q1 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Qube Research & Technologies (QRT) held 83,358 shares of Regeneron Pharmaceuticals worth $64.4M as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 58,825 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $45M.
  • Regeneron Pharmaceuticals made up 0.07% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #337 holding.
  • Qube Research & Technologies (QRT) first reported a position in Regeneron Pharmaceuticals in Q3 2018 and has held it in 22 quarters since.
  • Qube Research & Technologies (QRT)'s Regeneron Pharmaceuticals position peaked at $446M in Q1 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.